NASDAQ:SCPH - scPharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.50
  • Forecasted Upside: 156.72 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$4.09
▼ -0.1 (-2.39%)

This chart shows the closing price for SCPH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New scPharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SCPH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SCPH

Analyst Price Target is $10.50
▲ +156.72% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for scPharmaceuticals in the last 3 months. The average price target is $10.50, with a high forecast of $15.00 and a low forecast of $6.00. The average price target represents a 156.72% upside from the last price of $4.09.

This chart shows the closing price for SCPH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in scPharmaceuticals. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/24/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/22/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/19/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/18/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/17/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/9/2021SVB LeerinkInitiated CoverageMarket Perform$6.00High
7/2/2021HC WainwrightReiterated RatingBuy$15.00Low
12/8/2020BMO Capital MarketsLower Price TargetPositive ➝ Outperform$13.00 ➝ $10.00High
11/30/2020SVB LeerinkBoost Price TargetMarket Perform$11.00 ➝ $12.00High
6/23/2020BMO Capital MarketsReiterated RatingOutperform ➝ Market Perform$14.00High
5/27/2020SVB LeerinkLower Price TargetMarket Perform$12.00 ➝ $10.00Low
5/13/2020SVB LeerinkBoost Price TargetMarket Perform$7.00 ➝ $12.00Medium
5/13/2020HC WainwrightReiterated RatingBuy$13.00 ➝ $15.00Medium
10/15/2019HC WainwrightInitiated CoverageBuy$13.00Medium
6/14/2018SVB LeerinkLower Price TargetOutperform$20.00 ➝ $12.00Low
6/14/2018BMO Capital MarketsLower Price TargetOutperform ➝ Outperform$24.00 ➝ $14.00Low
6/14/2018Jefferies Financial GroupLower Price TargetBuy ➝ Buy$26.00 ➝ $12.00Medium
3/21/2018Jefferies Financial GroupReiterated RatingBuy$26.00High
12/12/2017Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$23.00Medium
12/12/2017SVB LeerinkInitiated CoverageOutperform ➝ Outperform$20.00Medium
12/12/2017BMO Capital MarketsInitiated CoverageOutperform$24.00Medium
(Data available from 1/18/2017 forward)

News Sentiment Rating

-0.01 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/22/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/21/2021
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
9/20/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/20/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/19/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/19/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/18/2022

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
scPharmaceuticals logo
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include furosemide, used as parenteral diuretic in treating heart failure and ceftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.
Read More

Today's Range

Now: $4.09
Low: $4.08
High: $4.32

50 Day Range

MA: $4.82
Low: $3.88
High: $6.02

52 Week Range

Now: $4.09
Low: $3.48
High: $8.20

Volume

24,490 shs

Average Volume

52,790 shs

Market Capitalization

$111.88 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.36

Frequently Asked Questions

What sell-side analysts currently cover shares of scPharmaceuticals?

The following equities research analysts have issued stock ratings on scPharmaceuticals in the last year: HC Wainwright, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for SCPH.

What is the current price target for scPharmaceuticals?

2 Wall Street analysts have set twelve-month price targets for scPharmaceuticals in the last year. Their average twelve-month price target is $10.50, suggesting a possible upside of 156.7%. HC Wainwright has the highest price target set, predicting SCPH will reach $15.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $6.00 for scPharmaceuticals in the next year.
View the latest price targets for SCPH.

What is the current consensus analyst rating for scPharmaceuticals?

scPharmaceuticals currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SCPH will outperform the market and that investors should add to their positions of scPharmaceuticals.
View the latest ratings for SCPH.

How do I contact scPharmaceuticals' investor relations team?

scPharmaceuticals' physical mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company's listed phone number is (617) 517-0730 and its investor relations email address is [email protected] The official website for scPharmaceuticals is www.scpharma.com.